Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/176832
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Camprubí, Daniel | - |
dc.contributor.author | Almuedo Riera, Alex | - |
dc.contributor.author | Martí Soler, Helena | - |
dc.contributor.author | Soriano Viladomiu, Alex | - |
dc.contributor.author | Hurtado, Juan Carlos | - |
dc.contributor.author | Subirà, Carme | - |
dc.contributor.author | Grau Pujol, Berta | - |
dc.contributor.author | Krolewiecki, Alejandro J. | - |
dc.contributor.author | Muñoz Gutiérrez, José | - |
dc.date.accessioned | 2021-04-28T09:48:24Z | - |
dc.date.available | 2021-04-28T09:48:24Z | - |
dc.date.issued | 2020-11-11 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/2445/176832 | - |
dc.description.abstract | Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2. | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0242184 | - |
dc.relation.ispartof | PLoS One, 2020, vol. 15, num. 11, p. e0242184 | - |
dc.relation.uri | https://doi.org/10.1371/journal.pone.0242184 | - |
dc.rights | cc-by (c) Camprubí, Daniel et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Farmacologia | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Pharmacology | - |
dc.title | Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 710488 | - |
dc.date.updated | 2021-04-28T09:48:24Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33175880 | - |
Appears in Collections: | Articles publicats en revistes (ISGlobal) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
710488.pdf | 364.87 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License